RA
CLDX icon

Rosalind Advisors’s Celldex Therapeutics CLDX Stock Holding History

Rosalind Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.44M Sell
200,000
-130,000
-39% -$4.2M 2.76% 12
2026
Q1 		$10.5M Buy
+330,000
New +$9M 4.21% 11

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rosalind Advisors's CLDX Position: Q2 2026 in Review

Rosalind Advisors reduced its Celldex Therapeutics (CLDX) stake by 39% in Q2 2026, selling an estimated $4.2M and leaving 200,000 shares worth $7.44M. The position accounts for 2.76% of the portfolio, ranked #12.

Rosalind Advisors first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $10.5M in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Rosalind Advisors held 200,000 shares of Celldex Therapeutics worth $7.44M as of Q2 2026.
  • Rosalind Advisors sold 130,000 Celldex Therapeutics shares in Q2 2026, an estimated $4.2M.
  • Celldex Therapeutics made up 2.76% of Rosalind Advisors's portfolio in Q2 2026, its #12 holding.
  • Rosalind Advisors first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Rosalind Advisors's Celldex Therapeutics position peaked at $10.5M in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.